IAP7 Rec'd PCT/PTO 28 AUG 2006

FORM PTO-1390 (REV. 01-2003)

US DÉPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER 129259

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) New U.S. Patent Application

INTERNATIONAL APPLICATION NO. PCT/JP2005/006004			INTERNATIONAL FILING DATE March 23, 2005	PRIORITY DATE CLAIMED March 23, 2004						
TITLE OF INVENTION TRICYCLIC BENZOPYRANE COMPOUND AS ANTI-ARRHYTHMIC AGENTS										
APPLICANT(S) FOR DO/EO/US Kazuhiko OHRAI; Yukihiko SHIGETA; Osamu UESUGI; Takumi OKADA; Tomoyuki MATSUDA										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2.	□;	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
4.		The US has been elected (Article 31).								
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
		a. 🛛 is attached hereto (required	o (required only if not communicated by the International Bureau).							
		. has been communicated by the International Bureau.								
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).								
6.	\boxtimes	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))								
		a. is attached hereto.								
		b. has been previously submit	ubmitted under 35 U.S.C. 154(d)(4).							
		c. The International Application								
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))								
		a. are attached hereto (require	ed only if not communicated by the International Bureau).							
		b. have been communicated by								
		c. have not been made; howe	ver, the time limit for making such a	amendments has NOT expired.						
		d.								
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:										
11.		An Information Disclosure Statement								
12.		An assignment document for reco	rding. A separate cover sheet in co	ompliance with 37 CFR 3.28 and 3.31 is included.						
13.	\boxtimes	A preliminary amendment.								
14.	\boxtimes	An Application Data Sheet under	pplication Data Sheet under 37 CFR 1.76.							
15.		A substitute specification.		.>						
16.		A power of attorney and/or change								
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.								
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).								
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
20.	\boxtimes	The International Search Report.	•							
ı										

IAP9 Rec'd PCT/PTO 28 AUG 2006

U.S. APPLICATION NO. (ILKNOWN) New U.S. Paten Application	97 (P.R. 1.5)	ATTORNEYS DOCKET NUMBER 129259							
21. The following fees	CALCULATIONS PTO USE ONLY								
BASIC NATIONAL FEE (37	\$300.00								
SEARCH FEE (37 CFR 1.49	\$400.00								
International preliminary exa the USPTO as IPEA or ISA industrial applicability for all national phase									
International search fee (37									
International search report per the search fee is paid									
All situations not provided for									
EXAMINATION FEE (37 CF	\$200.00								
International preliminary examination report or written opinion prepared by the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and industrial applicability for all claims presented in the application entering the national phase									
All situations not provided for	or above		\$ 200.00						
Surcharge of \$130.00 for fu	rnishing the search f	ee the examination fe	e or the oath or	\$					
declaration after the date of	commencement of	he national phase (37	CFR 1.492(h)).						
APPLICATION SIZE FEE					i I				
Total pages 439 - 100 =	339 ÷ 50	= †7	x 250 =	\$1750.00					
tround up to next integer									
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$					
TOTAL CLAIMS	55 - 20	= 35	x 50.00 =	\$1750.00					
INDEPENDENT CLAIMS	3 - 3	= 0	x 200.00 =	\$					
MULTIPLE DEPENDENT C	\$								
	\$4400.00								
Applicant claims small reduced by ½.	\$								
	\$4400.00								
Processing fee of \$130.00 f the earliest claimed priority	\$								
	\$4400.00								
Fee for recording the enclose accompanied by an appropriate to the control of the	\$								
accompanied by an appropri	late cover sheet (or	TOTAL FE	EES ENCLOSED =	\$4400.00					
	Amount to be								
ĺ				refunded:	\$				
				charged:	\$				
 a.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:									
OLIFF & BERRIDGE, PLC									
Customer Number: 25944 NAME: James A. Oliff REGISTRATION NUMBER: 27,075									
Date August 28, 2006 NAME: William P. Berridge									
Date <u>August 28, 2006</u>	REGISTRATION NUMBER: 30,024								